Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical — Technical Presentation (March 2020)

8 slides from Biohaven Pharmaceutical's technical presentation, Mar 31, 2020

  1. Slide 1: Rimegepant Migraine Prevention Topline Data Webcast

    NEURO INNOVATION BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES NYSE: BHVN © 2020 Biohaven Pharmaceuticals Inc. All rights reserved. Rimegepant Migraine Prevention Topline Data Webcast March 30, 2020

  2. Slide 2: Multiple Approaches Targeted for Acute & Preventive Treatment of Migraine

    Multiple Approaches Targeted for Acute & Preventive Treatment of Migraine MARCH 30, 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 2 NO JECTION™ CGRP Drug Delivery Platform 1. Exclusive World - Wide License with Catalent for use of Zydis ® Fast Dissolve Technology in our migraine prod

  3. Slide 3: Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC for Migraine Prevention

    Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine • Rimegepant 75 mg, dosed every other day, demonstrates statistically significant superiority, compared to placebo, on the primary endpoint of reduction in the mean nu

  4. Slide 4: Study BHV3000-305: Phase 2/3 Randomized Study of Rimegepant for Preventive Treatment

    Study BHV3000 - 305: Phase 3 Randomized Study Investigating the Efficacy and Safety of Rimegepant 75 mg for Preventive Treatment of Migraine 4 R randomization. Study 305 (N=741) Rimegepant 75 mg (n=370) Placebo (n=371) R 1:1 Baseline Observation Period 28 Day Treatment Phase Up to 12 Weeks Rimegepan

  5. Slide 5: Study Met Primary Endpoint – Significant Reduction in Monthly Migraine Days versus Placebo

    Study Met Primary Endpoint – Rimegepant Showed Significant Reduction in Monthly Migraine Days versus Placebo Mean Change from Baseline in Monthly Migraine Days at 3 Months • The average number of migraine days per month during the observation phase was 10.7 across all evaluable subjects. The figure

  6. Slide 6: Rimegepant Results in Patients with <14 and ≥14 Migraine Days in Observation

    - 3.3 - 4.1 - 5.3 - 6.4 -7 -6 -5 -4 -3 -2 -1 0 Rimegepant - Treated Patients with ≥14 Migraine Days in Observation Showed 6.4 Day Reduction vs. Baseline, & with <14 Migraine Days, Showed 4.1 Day Reduction Patients with <14 and ≥14 Migraine Days in Observation • In patients with ≥14 migraine days in

  7. Slide 7: Richard Lipton, MD – Biohaven Scientific Advisory Board

    Richard Lipton, MD ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 7 • Edwin S. Lowe Professor and Vice Chair of Neurology • Professor of Epidemiology and Population Health, Psychiatry and Behavioral Science, Albert Einstein College of Medicine • Director, Montefiore Headache Center • Fello

  8. Slide 8: Meeting Patient Needs. Growing Value.

    NYSE: BHVN © 2020 Biohaven Pharmaceuticals Inc. All rights reserved. NEURO INNOVATION Meeting Patient Needs. Growing Value. RIMEGEPANT MIGRAINE PREVENTION TOPLINE DATA WEBCAST MARCH 30, 2020

Biohaven Pharmaceutical Holding — Technical Presentation (March 2020) on 6ix